Zoetis’ (ZTS) “Hold (C-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their hold (c-) rating on shares of Zoetis (NYSE:ZTS) in a research report released on Wednesday morning,Weiss Ratings reports.

Other equities research analysts have also issued research reports about the stock. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $196.71.

Zoetis Price Performance

Shares of NYSE ZTS opened at $141.05 on Wednesday. The firm’s 50-day moving average price is $149.24 and its 200-day moving average price is $154.46. Zoetis has a 1-year low of $139.34 and a 1-year high of $196.55. The firm has a market capitalization of $62.51 billion, a P/E ratio of 24.28, a P/E/G ratio of 2.30 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business earned $1.56 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is currently 34.42%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank bought a new position in Zoetis in the 2nd quarter worth approximately $809,491,000. Nuveen LLC bought a new position in Zoetis in the 1st quarter worth approximately $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the period. Mackenzie Financial Corp boosted its holdings in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares during the period. Finally, Polen Capital Management LLC boosted its holdings in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.